ALDA Pharmaceuticals Corp.
TSX VENTURE : APH

ALDA Pharmaceuticals Corp.

March 22, 2007 11:25 ET

ALDA Initiates Funding Activities for Therapeutic Products

VANCOUVER, BRITISH COLUMBIA--(CCNMatthews - March 22, 2007) - ALDA Pharmaceuticals Corp. (TSX VENTURE:APH) ("ALDA") announces that it has commenced fund-raising activities in Europe through its contract with Rhone Alternative Marketing Partners ("RAMP") of Geneva, Switzerland. The proceeds of this financing will be used to complete the testing and registration of ALDA's T36® therapeutic products for the treatment and prevention of topical infections. Dr. Terrance Owen, President & CEO, states, "We have identified global markets of $10 Billion in our targeted disease areas. The funding agreement with RAMP that was announced on December 6, 2006 is intended to support ALDA's product development program and to secure a position in this major market. We are excited about the prospects for these proprietary therapeutic products and look forward to meeting with the European investment community."

About RAMP

RAMP has extensive experience in raising capital for companies in Europe and North America through its network of institutional investors in the major European financial centres.

About ALDA

ALDA's patent-pending T36® therapeutics contain multiple active ingredients in very low concentrations that act in concert to disrupt the physical structure of all infectious organisms rather than interfering with their metabolic pathways. The competitive advantage is a high degree of effectiveness and safety while preventing microbial resistance, side effects or toxicity.

Terrance G. Owen, Ph.D., MBA, President, CEO and Director

ALDA Pharmaceuticals Corp.

The TSX Venture Exchange does not accept responsibility for the adequacy or accuracy of this release.

Contact Information